Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial

Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis

“…In a dose-ranging trial with a trivalent Ia, Ib, III -CRM197-conjugate vaccine, a higher response against type Ia was seen with the (highest) 5 μg CPS dose for pregnant women who had undetectable antibody concentrations at baseline. No detectable effect on GMC was seen after receipt of a second dose of vaccine, 1 month later, in non-pregnant women 125 .…”

“…No clear effect of vaccination on colonisation was observed in a pregnancy trial with the Ia, Ib, III-CRM197 conjugate vaccine 125 .…”

Experience and challenges on influenza and pertussis vaccination in pregnant women

“…Novel vaccines currently under development targeted at pregnant women include a nanoparticle RSV post-fusion F protein vaccine, 61 which is currently being evaluated in a phase III study among pregnant women in Northern and Southern hemisphere countries (ClinicalTrials.gov identifier NCT02624947). Furthermore, the recent clinical development of a trivalent Group-B streptococcus conjugate vaccine (serotypes Ia, Ib, and II) in pregnant women, 62 is now being advanced into a hexavalent vaccine which will include serotypes (Ia, Ib, II, III, IV and V) responsible for >97% of invasive disease in infants with studies in pregnant women anticipated to begin in 2019. As reported in a systematic review, a Group-B streptococcus vaccine targeted at pregnant women has the potential of preventing 231,000 infant and maternal invasive disease cases, 41,000 stillbirths and at least 66,000 infant deaths 63 ; illustrating the potential of maternal vaccination to extend benefits beyond the infant alone.…”

Infección neonatal y tamizaje universal para Streptococcus agalactiae (β-hemolítico del grupo B) a la mujer embarazada: Recomendación técnica

“…El desarrollo de una vacuna para SBHGB dirigida a mujeres embarazadas podría potencialmente proporcionar protección a los niños durante el período mayor de vulnerabilidad a la enfermedad invasora (hasta los 3 meses de edad) 16 . Sin embargo, ni siquiera datos sobre estas nuevas estrategias preventivas han sido consistentes en lo que concierne a disminución de la colonización al momento del parto.…”

“…Sin embargo, ni siquiera datos sobre estas nuevas estrategias preventivas han sido consistentes en lo que concierne a disminución de la colonización al momento del parto. De hecho, un reciente estudio en fase IB/II donde vacunaron a mujeres embarazadas, demostró mayor porcentaje de colonización al momento del parto que en el tamizaje inicial 16 .…”